scholarly journals Application of evoked response audiometry for specifying aberrant gamma oscillations in schizophrenia

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Masaya Yanagi ◽  
Aki Tsuchiya ◽  
Fumiharu Hosomi ◽  
Satoshi Ozaki ◽  
Osamu Shirakawa
Keyword(s):  
Automated Analysis ◽  
Gamma Oscillations ◽  
Evoked Response ◽  
Assessment System ◽  
Therapeutic Interventions ◽  
Clinical Settings ◽  
Clinical Biomarkers ◽  
Clinical Otolaryngology ◽  
Analysis System ◽  
Evoked Response Audiometry

AbstractGamma oscillations probed using auditory steady-state response (ASSR) are promising clinical biomarkers that may give rise to novel therapeutic interventions for schizophrenia. Optimizing clinical settings for these biomarker-driven interventions will require a quick and easy assessment system for gamma oscillations in psychiatry. ASSR has been used in clinical otolaryngology for evoked response audiometry (ERA) in order to judge hearing loss by focusing on the phase-locked response detectability via an automated analysis system. Herein, a standard ERA system with 40- and 46-Hz ASSRs was applied to evaluate the brain pathophysiology of patients with schizophrenia. Both ASSRs in the ERA system showed excellent detectability regarding the phase-locked response in healthy subjects and sharply captured the deficits of the phase-locked response caused by aberrant gamma oscillations in individuals with schizophrenia. These findings demonstrate the capability of the ERA system to specify patients who have aberrant gamma oscillations. The ERA system may have a potential to serve as a real-world clinical medium for upcoming biomarker-driven therapeutics in psychiatry.

scholarly journals Application of Evoked Response Audiometry To Schizophrenia For Specifying 40-Hz Aberrant Gamma Oscillations In A Real-World Clinical Setting

2021 ◽  
Author(s):  
Masaya Yanagi ◽  
Aki Tsuchiya ◽  
Fumiharu Hosomi ◽  
Satoshi Ozaki ◽  
Osamu Shirakawa
Keyword(s):  
Real World ◽  
Clinical Setting ◽  
Automated Analysis ◽  
Gamma Oscillations ◽  
Evoked Response ◽  
Assessment System ◽  
Therapeutic Interventions ◽  
Clinical Biomarkers ◽  
Evoked Response Audiometry ◽  
40 Hz

Abstract Gamma oscillations probed using auditory steady-state response (ASSR) are promising clinical biomarkers that may address novel therapeutic interventions for schizophrenia. Optimizing clinical settings for these biomarker-driven interventions will require a quick and easy assessment system of gamma oscillations in psychiatry. ASSR has been used in clinical otolaryngology for evoked response audiometry (ERA) to judge hearing loss by focusing on the phase-locked response detectability in an automated analysis system. Herein, a standard ERA system was applied to evaluate the brain pathophysiology of patients with schizophrenia with 40-Hz ASSR. The 40-Hz ASSR in the ERA system showed excellent detectability of the phase-locked response in healthy subjects, which sharply captured the deficits of the phase-locked response caused by aberrant gamma oscillations in individuals with schizophrenia. These findings reveal the availability of the ERA system in specifying patients who have aberrant 40-Hz gamma oscillations. The ERA system may have a potential to serve as a real-world clinical setting for upcoming biomarker-driven therapeutics in psychiatry.

Assessment of Hearing Impairment in NICU Graduates by Otoacoustic Emission and Brainstem Evoked Response Audiometry Tests

2020 ◽  
Vol 34 (3) ◽  
pp. 109-117
Author(s):  
Aparna Aradhana ◽  
Gadadhar Sarangi ◽  
Prasant Saboth ◽  
Radha Tripathy
Keyword(s):  
Risk Factors ◽  
Hearing Impairment ◽  
Very Low Birth Weight ◽  
Birth Asphyxia ◽  
Otoacoustic Emission ◽  
Evoked Response ◽  
Complete Evaluation ◽  
Brainstem Evoked Response Audiometry ◽  
Tertiary Teaching ◽  
Evoked Response Audiometry

Objectives: To find out the incidence of hearing impairment in Neonatal Intensive Care Unit (NICU)-admitted newborns and to correlate between several risk factors. Design: Prospective observational study. Setting: In a tertiary teaching hospital of Odisha between October 2014 and October 2016. Study population: 100 newborns delivered in the institution and admitted in NICU with usual indications and risk factors that underwent otoacoustic emission 1 and 2 (OAE1, OAE2) and Brainstem Evoked Response Audiometry (BERA). Results: 84 babies in OAE1 and 86 babies in OAE2 got “pass” results. In BERA test, 92 babies got normal waveform. 7 (13.7%) of 51 premature babies, 5 (38.5%) of 13 very low birth weight babies, 7 (17.5%) of 40 babies receiving ototoxic medication for >5 days, 7 (31.8%) of 22 babies with hyperbilirubinemia, 6 (42.9%) of 14 babies with sepsis, 5 (20%) of 20 babies with birth asphyxia, 3 (60%) of 5 babies under mechanical ventilation for >5 days, 1 baby with ear abnormality, and 1 (50%) out of 2 babies with congenital infections had hearing impairment and statistically significant association with abnormal OAE and BERA test. Conclusion: There is high incidence of hearing loss in NICU-admitted newborns. OAE and BERA both should be performed for complete evaluation of hearing. Important risk factors are elaborated. Predischarge hearing assessment in NICU is most important.

A study of brainstem evoked response audiometry in high-risk infants and children under 10 years of age

2015 ◽  
Vol 21 (2) ◽  
pp. 134 ◽  
Author(s):  
Ramanathan Thirunavukarasu ◽  
GaneshKumar Balasubramaniam ◽  
RameshBabu Kalyanasundaram ◽  
Gitanjali Narendran ◽  
Sajee Sridhar
Keyword(s):  
High Risk ◽  
Evoked Response ◽  
Infants And Children ◽  
Brainstem Evoked Response Audiometry ◽  
High Risk Infants ◽  
Evoked Response Audiometry

Attenuation of the Early Gamma Oscillations During the Sensory-Evoked Response in the Neonatal Rat Barrel Cortex

2016 ◽  
Vol 6 (4) ◽  
pp. 575-577 ◽  
Author(s):  
Dmitrii Suchkov ◽  
Mikhail Sintsov ◽  
Lyailya Sharipzyanova ◽  
Roustem Khazipov ◽  
Marat Minlebaev
Keyword(s):  
Barrel Cortex ◽  
Gamma Oscillations ◽  
Evoked Response ◽  
Neonatal Rat ◽  
Sensory Evoked

scholarly journals Role of Brainstem Evoked Response Audiometry in Evaluating Sensorineural Hearing Loss in Diabetic Patients

2021 ◽  
Vol 29 (2) ◽  
pp. 182-188
Author(s):  
Deepika Goswami ◽  
Saurabh Srivastava ◽  
Anuja Bhargava ◽  
Syed M Faiz ◽  
Zeba Siddiqi ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Auditory Pathway ◽  
Evoked Response ◽  
Sensorineural Hearing ◽  
Diabetic Patients ◽  
Brainstem Evoked Response Audiometry ◽  
Group I ◽  
Absolute Latency ◽  
Evoked Response Audiometry

Introduction Diabetes has become a global epidemic. Hearing loss has been long associated with diabetes. Brainstem Evoked Response Audiometry (BERA) is an objective, non-invasive, electro diagnostic test that not only evaluates the functional integrity of the subcortical auditory pathway but also provides topo-diagnosis of hearing loss. This study aims to identify the role BERA in detecting hearing loss early in diabetic patients.Materials and Methods In this study a total of 210 patients were taken and subjected to blood glucose levels followed by PTA were divided into two groups. Group I (n=105) consisted of diabetic patients with sensorineural hearing loss (SNHL) and Group II (n=105) had age and sex matched non-diabetics with SNHL. All the patients were evaluated with BERA.Results All the patients were subjected to Brain Stem Evoked Response Audiometry (BERA). Absolute latency of Wave I, III, V, I-III, III-V and I-V were assessed for both the ears. In both ear Absolute latency were significantly higher in diabetics as compared to non-diabetic patientsConclusion The findings of present study showed that the severity of hearing loss was significantly higher in diabetic patients as compared to non-diabetic controls. Level of glycemic control showed a possible link with severity of hearing loss.

scholarly journals A comparison of the Mouse Song Analyzer and DeepSqueak ultrasonic vocalization analysis systems in C57BL/6J, FVB.129, and FVB mice

2021 ◽  
Author(s):  
Matthew S Binder ◽  
Zachary P Pranske ◽  
Joaquin N Lugo
Keyword(s):  
Fundamental Frequency ◽  
Vocal Communication ◽  
Automated Analysis ◽  
Ultrasonic Vocalization ◽  
Ultrasonic Vocalizations ◽  
Automated System ◽  
Two Systems ◽  
Similar Quantity ◽  
Analysis System

Vocal communication is an essential behavior in mammals and is relevant to human neurodevelopmental conditions. Mice produce communicative vocalizations, known as ultrasonic vocalizations (USVs), that can be recorded with various programs. The Mouse Song Analyzer is an automated analysis system, while DeepSqueak is a semi-automated system. We used data from C57BL/6J, FVB.129, and FVB mice to compare whether the DeepSqueak and Mouse Song Analyzer systems measure a similar total number, duration, and fundamental frequency of USVs. We found that the two systems detected a similar quantity of USVs for FVB.129 mice (r= .90, p< .001), but displayed lower correlations for C57BL/6J (r= .76, p< .001) and FVB mice (r= .60, p< .001). We also found that DeepSqueak detected significantly more USVs for C57BL/6J mice than the Mouse Song Analyzer. The two systems detected a similar duration of USVs for C57BL/6J (r= .82, p< .001), but lower correlations for FVB.129 (r= .13, p< .001) and FVB mice (r= .51, p< .01) were found, with DeepSqueak detecting significantly more USVs per each strain. We found lower than acceptable correlations for fundamental frequency in C57BL/6J (r= .54, p< .01), FVB.129 (r= .76, p< .001), and FVB mice (r= .07, p= .76), with the Mouse Song Analyzer detecting a significantly higher fundamental frequency for FVB.129 mice. These findings demonstrate that the strain of mouse used significantly affects the number, duration, and fundamental frequency of USVs that are detected between programs. Overall, we found that DeepSqueak is more accurate than the Mouse Song Analyzer.

scholarly journals Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer

2021 ◽  
Vol 22 (18) ◽  
pp. 9953
Author(s):  
Mai Tanaka ◽  
Dietmar W. Siemann
Keyword(s):  
Signaling Pathway ◽  
Receptor Tyrosine Kinase ◽  
Therapeutic Agents ◽  
Therapeutic Interventions ◽  
Therapeutic Resistance ◽  
Clinical Settings ◽  
Affinity Ligand ◽  
Current State ◽  
Cancer Types ◽  
High Affinity Ligand

Many signaling pathways are dysregulated in cancer cells and the host tumor microenvironment. Aberrant receptor tyrosine kinase (RTK) pathways promote cancer development, progression, and metastasis. Hence, numerous therapeutic interventions targeting RTKs have been actively pursued. Axl is an RTK that belongs to the Tyro3, Axl, MerTK (TAM) subfamily. Axl binds to a high affinity ligand growth arrest specific 6 (Gas6) that belongs to the vitamin K-dependent family of proteins. The Gas6/Axl signaling pathway has been implicated to promote progression, metastasis, immune evasion, and therapeutic resistance in many cancer types. Therapeutic agents targeting Gas6 and Axl have been developed, and promising results have been observed in both preclinical and clinical settings when such agents are used alone or in combination therapy. This review examines the current state of therapeutics targeting the Gas6/Axl pathway in cancer and discusses Gas6- and Axl-targeting agents that have been evaluated preclinically and clinically.

Sign in / Sign up

Export Citation Format

Share Document